Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433379 · ClinicalTrials.gov registry record · NA
Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction
A NA study of Ventricular Tachycardia and Ventricular Fibrillation, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 1,173
- Enrollment target
- 20
- Study locations
NCT02433379 is a NA study of Ventricular Tachycardia and Ventricular Fibrillation that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,173 participants, above the 247-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (375% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT02433379, a NA study of Ventricular Tachycardia and Ventricular Fibrillation, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,173 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study assesses the 18-month incidence of inappropriate shocks in subjects implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) for primary prevention of sudden cardiac death. Devices are to be programmed with zone cutoffs at 200 bpm and 250 bmp in order to mimic the programming settings for transvenous ICDs in the MADIT RIT study. The incidence of inappropriate S-ICD shocks will be compared to the incidence of inappropriate shocks observed in the MADIT RIT study.
Conditions Studied
Interventions
- DEVICE EMBLEM S-ICD System
Study Locations (20)
California
- Glendale Adventist Medical Center - Glendale
- Sharp Grossmont Hospital - La Mesa
- University of Southern California Hospital - Los Angeles
- Alta Bates Medical Center - Oakland
- St. Joseph Hospital - Orange
- Good Samaritan Hospital - San Jose - San Jose
- Harbor UCLA Medical Center - Torrance
Florida
- Baptist Medical Center - Jacksonville
- Florida Hospital - Orlando
- Tallahassee Memorial Hospital - Tallahassee
Alabama
- Alabama Cardiovascular Group - Birmingham
- Huntsville Hospital - The Heart Center, PC - Huntsville
Arizona
- Mercy Gilbert Medical Center - Gilbert
- Mayo Clinic Phoenix - Phoenix
Georgia
- Emory University Hospital - Atlanta
- University Hospital - Augusta
Illinois
- CorVita Science Foundation - Chicago
- Northwestern Memorial Hospital - Chicago
Connecticut
- Yale University School of Medicine - New Haven
Delaware
- Cardiology Physicians PA - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,173 participants |
| Start Date | 2015-06-09 |
| Est. Completion | 2019-12-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02433379
The ClinicalTrials.gov registry entry for NCT02433379 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,173 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 247-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (375% higher). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ventricular Tachycardia appearing as the primary indexed condition, and to 1 intervention - of which EMBLEM S-ICD System is the first listed.
NCT02433379 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02433379 about?
NCT02433379 is a clinical study titled "Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction". This study assesses the 18-month incidence of inappropriate shocks in subjects implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) for primary prevention of sudden cardiac death. Devices are to be programmed with zone cutoffs at 200 bpm and 250 bmp in order to mimic the programm...
What is the current status of trial NCT02433379?
This trial is currently completed. It is a NA study. The enrollment target is 1,173 participants. The study started on 2015-06-09. Estimated completion is 2019-12-06.
What conditions does trial NCT02433379 study?
This clinical trial studies the following conditions: Ventricular Tachycardia, Ventricular Fibrillation, Low Cardiac Output.
What interventions are being tested in trial NCT02433379?
The interventions under investigation include: EMBLEM S-ICD System (DEVICE).
Who is sponsoring clinical trial NCT02433379?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02433379 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ventricular Tachycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ventricular Tachycardia Mechanisms
RECRUITING · NA
-
Randomized Assessment of TcMS for VT Storm
RECRUITING · NA
-
Cardiac Radioablation for VT
RECRUITING · NA
-
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
RECRUITING · NA
-
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
RECRUITING · NA
-
The Z Stitch Early Bed Rest Assessment Study
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.